Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

计划入组 439 人 · 首次发布于 2011 年 12 月 20 日

NNRTI/PI Toxicity Switch to Darunavir Study

计划入组 12 人 · 首次发布于 2008 年 10 月 2 日

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

计划入组 19 人 · 首次发布于 2011 年 10 月 24 日

NNRTI (AiCuris)

NNRTI(AiCuris GmbH & Co. KG)

Bavtavirine

Delavirdine Approved as Second NNRTI for Anti-HIV Combination Therapy

HIV Drug Resistance Declining in South Africa, but Integrase Inhibitor Resistance Requires Vigilance

FDA Accepts Merck's Application for Novel Two-Drug HIV Regimen Doravirine/Islatravir